

The **ONLY** FDA-approved treatment for reducing excess abdominal fat in people with HIV and lipodystrophy.<sup>1</sup>

There is more to treating people with HIV than viral suppression

# REDUCE THE IMPACT OF CENTRAL ADIPOSITY



# Hear how EGRIFTA SV® could help a patient like Tim



FDA = Food and Drug Administration; HIV = human immunodeficiency virus.

#### IMPORTANT SAFETY INFORMATION

#### Indication

EGRIFTA SV® is indicated for the reduction of excess abdominal fat in people with HIV and lipodystrophy.

#### **Limitations of Use:**


- The impact and safety of EGRIFTA SV® on cardiovascular health have not been studied.
- EGRIFTA SV® is not indicated for weight loss management.
- It is not known whether taking EGRIFTA SV® helps improve compliance with anti-retroviral medications.

### **Understanding and identifying** central adiposity in HIV


People with HIV (PWHIV) have an increased risk in developing excess visceral abdominal fat 2

- Excess visceral abdominal fat is the abnormal accumulation of visceral fat in the abdominal cavity and is present around internal organs.3
- The pathogenesis of excess visceral abdominal fat in PWHIV appears to be multifactorial, including contributions from:3
  - Antiretroviral therapy (ART)
  - HIV infection itself
  - Growth hormone (GH) deficiency<sup>4</sup>

### The location of fat matters: Comparing subcutaneous fat vs. visceral abdominal fat



Subcutaneous fat



Visceral abdominal fat

### **Identify excess visceral abdominal fat** with 3 simple steps<sup>3</sup>



Palpate the midsection for firmness or rigidity



Measure waist and hip circumferences



BMI and WC are waist-to-hip ratio<sup>†</sup> independently associated with excess visceral abdominal fat.<sup>5,6</sup>



**Indicators for** 

excess visceral abdominal fat:3\*†

<sup>\*</sup> Waist-to-hip ratio = waist circumference/hip circumference. † Reference values are based on inclusion criteria in clinical trials.


WC = waist circumference.

### **EGRIFTA SV®:**

# A unique mechanism of action that helps break down excess visceral abdominal fat in PWHIV<sup>1</sup>

### GH deficiency has been observed in PWHIV.7

EGRIFTA SV® is an analog of GHRH that stimulates the body to secrete its own GH in a pulsatile manner, resulting in both anabolic and lipolytic effects.¹



### The solution to excess visceral abdominal fat may not be diet and exercise alone.

GH = growth hormone; GHRH = growth hormone-releasing hormone.

### **IMPORTANT SAFETY INFORMATION**

#### **Contraindications:**

Do not use EGRIFTA SV® if patient:

- Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
- · Has active cancer.
- Is allergic to tesamorelin or any of the ingredients in EGRIFTA SV®.
- Is pregnant or planning to become pregnant.

# Patients who received *EGRIFTA*® experienced a significant reduction in excess visceral abdominal fat<sup>1†‡</sup>

Main Phase 26 weeks




**16%** Average reduction in excess visceral abdominal fat<sup>1‡</sup>

Extension Phase 52 weeks



18%

An expert panel in agreement with the FDA determined that a ≥8% decrease in excess visceral abdominal fat was clinically significant.9



E = EGRIFTA; P = placebo. First letter refers to Main Phase, second letter refers to Extension Phase.

#### IMPORTANT SAFETY INFORMATION

#### **Drug Interactions**

- EGRIFTA SV® had no significant impact on the pharmacokinetic profiles of simvastatin in healthy subjects.
- Monitor patients for potential interactions when administering EGRIFTA SV® in combination with other drugs known to be metabolized by CYP450 liver enzyme.
- Patients on glucocorticoids may require dosage adjustment upon initiation of EGRIFTA SV®.

In a post-hoc responder analysis<sup>\*†</sup> of data from two multicenter, randomized, double-blind, placebo-controlled clinical trials:

# EGRIFTA® responders experienced a significant reduction in excess visceral abdominal fat and waist circumference at 26 weeks that was maintained for up to 52 weeks<sup>10\*</sup>





**27%** Average reduction in excess visceral abdominal fat\*†





Among responders, excess visceral abdominal fat:10†

- Decreased from 187 cm<sup>2</sup> to 137 cm<sup>2</sup>, approaching normal levels (<130 cm<sup>2</sup>) by Week 26.
- Was, on average, below normal levels (mean VAT: 129 ± 48 cm<sup>2</sup>) at Week 52.

The results of the post-hoc analysis were not part of the NDA, and therefore were not reviewed by the FDA to support the approval of EGRIFTA®.

The safety and effectiveness of EGRIFTA  $SV^{\otimes}$  has been established based on adequate and well-controlled studies with EGRIFTA $^{\otimes}$  (tesamorelin for injection).

EGRIFTA SV® is not indicated for weight loss management.

EGRIFTA SV® is not approved for use in clinical conditions other than the reduction of excess abdominal fat.

### EGRIFTA SV® may increase lean body mass by up to 5 lbs and has no BMI requirement. 1,10†

FDA = Food and Drug Administration; NDA = New Drug Application.

#### IMPORTANT SAFETY INFORMATION

### **Use in Specific Populations**

Lactation: Mothers should not breastfeed if they receive EGRIFTA SV®.

**Pediatric Use**: Safety and effectiveness in pediatric patients have not been established. **Geriatric Use**: There is no information on the use of *EGRIFTA SV*<sup>®</sup> in patients greater than 65 years of age.

<sup>\*</sup>In two multicenter, randomized, placebo-controlled trials. The primary outcome for these trials was change from Week 26 to Week 52 in excess visceral abdominal fat by treatment group (EGRIFTA® Week 0–52 or EGRIFTA® Week 0–26 and placebo Week 26–52). †A single-slice CT scan was used to quantify excess visceral abdominal fat.

# Building on 10+ years of established safety with EGRIFTA®1\*

### EGRIFTA SV® is generally well tolerated

Within the Phase 3 studies, 740 PWHIV who had lipodystrophy and excess abdominal fat received *EGRIFTA®*; of these, 543 received *EGRIFTA®* during the initial 26-week placebocontrolled Main Phase studies.<sup>1</sup>

The most commonly reported adverse events were:1

- Hypersensitivity reactions (rash, urticaria)
- Edema-related reactions (e.g., arthralgia, pain in extremity, peripheral edema, and carpal tunnel syndrome)
- · Hyperglycemia
- Injection-site reactions (e.g., injection site erythema, pruritus, pain, urticaria, irritation, swelling, and hemorrhage)

The safety and effectiveness of EGRIFTA SV® has been established based on adequate and well-controlled studies with EGRIFTA® (tesamorelin for injection).

### EGRIFTA® was approved in 2010 and EGRIFTA SV® in 2019.

#### IMPORTANT SAFETY INFORMATION

#### **Warnings and Precautions**

- Increased risk of neoplasms: Preexisting malignancy should be inactive, and its treatment complete prior to starting EGRIFTA SV®. EGRIFTA SV® should be discontinued if the patient has evidence of recurrent malignancy.
- **Elevated IGF-1**: Monitor regularly IGF-1 levels in all patients during *EGRIFTA SV*® therapy. Consider discontinuing in patients with persistent elevations (e.g., >3 SDS).
- Fluid retention: May include edema, arthralgia, and carpal tunnel syndrome.
- **Glucose intolerance or diabetes mellitus**: May develop with *EGRIFTA SV*® use. Evaluate glucose status prior to and during therapy with *EGRIFTA SV*®.
- **Hypersensitivity reactions**: Advise patients to seek immediate medical attention and discontinue treatment if suspected.
- **Injection-site reactions**: Advise patients to rotate injection sites to different areas of the abdomen to decrease injection-site reactions.
- Increased mortality in patients with acute critical illness: Consider discontinuation in critically ill patients.

<sup>\*</sup>The safety of EGRIFTA SV® (2 mg/vial formulation) has been established based on clinical trials conducted with EGRIFTA® (1 mg/vial formulation). Adverse events for the 1.4 mg dose (2 mg/vial formulation) of EGRIFTA SV® are expected to be similar to those observed with the 2 mg dose (1 mg/vial formulation) of EGRIFTA®.

### EGRIFTA SV® dosing & administration<sup>1</sup>

- Once-daily dosing of 1.4 mg (small volume of only 0.35 mL reconstituted solution)
- Store at room temperature (no refrigeration required)
- Small needle size (1/2 30-gauge needle)



Medication box

Injection box

Available in a package of 2 boxes with a 30-day supply

### Contact THERA patient support® to get your patients started with EGRIFTA SV® today!



Our Nurse Navigators can enhance your patients' experience and promote treatment adherence.

# The **ONLY** FDA-approved treatment for reducing excess abdominal fat in people with HIV and lipodystrophy.<sup>1</sup>

# 27% demonstrated reduction in excess visceral abdominal fat in responders after 26 weeks of treatment.<sup>10</sup>

### EGRIFTA SV® (tesamorelin) for injection: Building on 10+ years of established safety.<sup>1</sup>

### EGRIFTA SV® has a weight-neutral effect, and may increase lean body mass by up to 5 pounds and has no BMI requirement.<sup>1,10</sup>

EGRIFTA SV<sup>®</sup> is not approved for use in clinical conditions other than the reduction of excess abdominal fat.

EGRIFTA SV® is not indicated for weight loss management.

#### IMPORTANT SAFETY INFORMATION

#### **Adverse Reactions**

The most commonly reported adverse reactions include injection-site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

For complete disclosure of *EGRIFTA* SV® product information, please read the **Full Prescribing Information, Patient Information, and Patient Instructions for Use.** Available at EgriftaSV.com.

For more information about *EGRIFTA SV*®, contact **\*\*\*: THERA** patient support\* toll-free at 1-833-23THERA (1-833-238-4372). To report suspected adverse reactions, contact **\*\*\*: THERA** patient support\* toll-free or FDA at 1-800-FDA-1088 or **www.fda.gov/medwatch**.

References: 1. EGRIFTA SV® (tesamorelin) for injection Prescribing Information. Theratechnologies Inc. February 2024. 2. Moyle G, Moutschen M, Martínez E, et al. Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection. AIDS Rev. 2010;12(1):3-14. 3. Lake JE, et al. Practical review of recognition and management of obesity and lipohypertrophy in human immunodeficiency virus infection. Clin Infect Dis. 2017;64(10):1422-1429. 4. Rietschel, P, Hadigan C, Corcoran C, et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. J Clin Endocrinol Metabolism. 2001;86;504-10. 5. Janssen I, Heymsfield SB, Allison DB, Kotler DP, Ross R. Body mass index and waist circumference independently contribute to the prediction of nonabdominal, abdominal subcutaneous, and visceral fat. Am J Clin Nutr. 2002;75(4):683-688. 6. Joy T, Keogh HM, Allison DB, Hadigan C, et al. Relationship of Body Composition to BMI in HIV-Infected Patients with Metabolic Abnormalities. J Acquir Immune Defic Syndr. 2008;47(2):174-84. 7. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015;25(2):59-65. 8. Bedimo B, Gonzalo T, McGary CS, et al. Visceral fat reduction with tesamorelin associated with metabolic syndrome reversal (abstract 709). Conference on Retroviruses and Opportunistic Infections. 2023. 9. Snyder SW. Regulatory Considerations for the Treatment of Lipodystrophy. Report of a Forum for Collaborative HIV Research Roundtable discussion. October 25, 2004; Washington DC. 10. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651.



